Home » Reports » USA Broker Ratings » Tokai Pharmaceuticals Inc 269.3% Potential Upside Indicated by Oppenheimer

Tokai Pharmaceuticals Inc 269.3% Potential Upside Indicated by Oppenheimer

Tokai Pharmaceuticals Inc using SYMBOL code NASDAQ:TKAI had its stock rating noted as ‘Coverage Initiated’ with the recommendation being set at ‘OUTPERFORM’ this morning by analysts at Oppenheimer. Tokai Pharmaceuticals Inc are listed in the Health Care sector within NASDAQ. Oppenheimer have set their target price at 38 USD on its stock. This now indicates the analyst believes there is a potential upside of 269.3% from the opening price of 10.29 USD. Tokai Pharmaceuticals Inc NASDAQ:TKAI has a 50 day moving average of 12.61 USD and a 200 day moving average of 14.37 USD. The 1 year high for the share price is 30 USD while the year low share price is currently 9.67 USD.

 

Tokai Pharmaceuticals Inc NASDAQ:TKAI is a biopharmaceutical company. The Company is focused on developing therapies for the treatment of prostate cancer and other hormonally-driven diseases. The Company’s drug candidate, Galeterone, is a multi-targeted, oral small molecule drug candidate for the treatment of prostate cancer that disrupts androgen receptor signaling through three mechanisms of action. Galeterone acts by disrupting the androgen receptor signaling pathway, which is a pathway that drives prostate cancer growth. The Company has a drug discovery program, ARDA (Androgen Receptor Modulation Optimized for Response). ARDA is focused on the identification and evaluation of compounds with potent androgen receptor degradation activity targeted to patients with androgen receptor signaling diseases, including prostate cancer.

Join us on our new LinkedIn page

Follow us on LinkedIn